FDA approves novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome.
Fall vaccination plans continue to expose political fault lines in the US, a new poll shows.
Administering vaccines during a global pandemic, amidst a flood of misinformation, left pharmacists with unique challenges.
Abrysvo is currently available in a kit containing a vial of lyophilized antigen component, a prefilled syringe containing diluent and a vial adapter.
Bacterial pneumonia treatment now available; FDA deny anaphylaxis treatment; flu vaccine efficacy results; flexible dosing for Talicia; change in the therapeutic equivalence for organ rejection drug generic.
Routine annual influenza vaccination is recommended for all patients 6 months of age and older who have no contraindications.
After 2010, all invasive pneumococcal infection serotypes were those not included in 13-valent pneumococcal conjugate vaccine.
Vaccination linked to reduced odds ratio of COVID-19-related emergency department or urgent care encounter, outpatient visits.
Similar immune response and no increase in rate of reactogenicity events seen with coadministration vs COVID-19 vaccine alone.
Findings seen for 50 most common questions about false information, myths, and false and true contraindications.
New booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
Interim analysis showed that the mRNA-1010 vaccine met all coprimary endpoints.
Shorter disease course with less mucosal disease seen on reinfection vs initial infection.
Interim data show vaccine effectiveness of 51.9% in 5 South American countries during their flu season.
The bivalent Pfizer-BioNTech and Moderna COVID-19 vaccines are no longer authorized for use in the United States.
Findings from this survey were presented at the October 2022 ACIP meeting.
The BA.2.86 variant has multiple genetic differences from previous versions of SARS-CoV-2.
The study was conducted from 2009 through 2021.
However, poll reveals that once aware of the vaccine, about two-thirds are interested in receiving it.
